Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012

• Published in: Vaccine Vol. 33; no. 2; pp. 359 - 366
• Main Authors: Lepoutre, A, Varon, E, Georges, S, Dorléans, F, Janoir, C, Gutmann, L, Lévy-Bruhl, D
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 03.01.2015; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Allergy and Immunology; Child; Child, Preschool; Female; France; France - epidemiology; Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage; Hospitals; Humans; Immunization; Incidence; Infant; Infant, Newborn; Invasive pneumococcal disease; Laboratories; Male; Meningitis; Middle Aged; Pneumococcal conjugate vaccines; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumonia; Population Surveillance; Serogroup; Serotype replacement; Serotyping; Streptococcus pneumoniae; Time Factors; Vaccination; Vaccine impact; Vaccines; Vaccines, Conjugate - administration & dosage; Young Adult; France; Vaccine impact; Serotype replacement; Invasive pneumococcal disease; Population surveillance; Pneumococcal conjugate vaccines; France
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.11.011

Highlights • PCVs coverage increased from 56% in those born in 2004 to 94% in those born in 2008. • After PCV7, IPD decreased in children <2 years, but not in older age-groups. • After PCV13, IPD declined in children <2 years, and in other non-targeted age-groups. • For the whole PCV7 + PCV13 period, IPD declined only in children aged 0–4 years.